3B Films Ltd. IPO

3B Films has informed that the provision of Annual Secretarial Audit Report for the year ended 31st March,2026 under Regulation 24(A) of SEBI (Listing Obligations and Disclosures Requirements) (Amendments) Regulation, 2018 is not applicable to the Company. Further the company has informed that as per Regulation 15(2) (b) of SEBI (Listing Obligations and Disclosures Requirements), the compliance with Corporate Governance provisions as specified in Regulation 24A shall not apply in respect of: 1. The listed entity having Paid-up Capital not exceeding Rs.10.00 Crore and Net worth not exceeding Rs.25 Crores as on 31.03.2026. 2. The listed entity whose specified securities are listed on SME Exchange platform. Since we do not fall under the above specified limits therefore compliance as per Regulation 24(A) of SEBI LODR Regulations, 2015 is not applicable to the Company for the Year ended March 31, 2026.

The above information is a part of company’s filings submitted to BSE.

Goldline Pharmaceutical 

• Goldline Pharmaceutical is coming out with an initial public offering (IPO) of 27,00,000 shares in a price band of Rs 41-43 per equity share. 
• The issue will open on May 12, 2026 and will close on May 14, 2026.
• The shares will be listed on SME Platform of BSE.
• The face value of the share is Rs 10 and is priced 4.1 times of its face value on the lower side and 4.3 times on the higher side.
• Book running lead manager to the issue is Cumulative Capital.
• Compliance Officer for the issue is Ruchi Sanket Modi.

Profile of the company

Goldline Pharmaceutical is engaged in the business of marketing pharmaceutical products under the brand name ‘Goldline’. Its product portfolio is organized into five distinct segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. The pharmaceutical products marketed under the ‘Goldline’ brand are not manufactured by the company. Instead, it enters into contractual arrangements with third-party manufacturers, who produce the products based on its market research, demand analysis, and specifications. These contractual arrangements ensure that all products meet the requisite quality standards and regulatory norms.

The products are marketed and sold exclusively under the ‘Goldline’ brand. Its customers primarily comprise distributors, who further supply to retailers and wholesalers, forming the main channel of distribution to the end-users. Presently, it maintains contractual arrangements with 15 manufacturers and 8 distributors, ensuring a stable supply chain and consistent market presence.

Under the third-party manufacturing model, the primary responsibility and product liability in respect of each formulation rests with the respective manufacturer. The manufacturer is solely responsible for ensuring that products are manufactured in compliance with the Drugs and Cosmetics Act, 1940 and the rules made thereunder, and that such products always conform to the specifications prescribed under the applicable pharmacopoeia standards. Notwithstanding the above, as a responsible organisation operating in the pharmaceutical sector, the company accords highest priority to addressing any quality-related concerns or complaints pertaining to products marketed under its brand.

Proceed is being used for:

• Repayment of all or a portion of certain outstanding borrowings availed by the company
• General corporate purposes

Industry overview

Indian pharmaceutical industry is known for its generic medicines and low-cost vaccines globally. Transformed over the years as a vibrant sector, presently Indian pharma ranks third in pharmaceutical production by volume. The Pharmaceutical industry in India is the third largest in the world in terms of volume and 14th largest in terms of value. The pharma sector currently contributes to around 1.72% of the country’s GDP. The Indian pharmaceuticals industry is expected to grow 9-11% in the financial year 2024.

In FY23, the Indian pharma market saw a year-on-year growth of nearly 5%, reaching $49.78 billion. During FY18 to FY23, the Indian pharmaceutical industry logged a compound annual growth rate (CAGR) of 6-8%, primarily driven by an 8% increase in exports and a 6% rise in the domestic market. Major Segments of the Pharmaceutical Industry are Generic drugs, OTC Medicines and API/Bulk Drugs, Vaccines, Contract Research & Manufacturing, Biosimilars & Biologics. Market size of India pharmaceuticals industry is expected to reach $65 billion by 2024, $130 billion by 2030 and $450 billion market by 2047. India is 3rd largest market for APIs globally, 8% share in the Global API Industry, 500+ different APIs are manufactured in India, and it contributes 57% of APIs to the prequalified list of the WHO. Pharmaceutical is one of the top ten attractive sectors for foreign investment in India. The pharmaceutical exports from India reach more than 200 nations around the world, including highly regulated markets of the USA, West Europe, Japan, and Australia.

The Government has put in place an investor-friendly Foreign Direct Investment (FDI) policy to promote investment in the sector. 100% foreign investment is allowed under automatic route in Medical Devices. In pharmaceuticals, up to 100% FDI in greenfield projects and up to 74% FDI in brownfield projects is allowed under the automatic route. Foreign investment beyond 74% in brownfield projects requires Government approval. After the abolition of the Foreign Investment Promotion Board (FIPB) in May 2017, the Department of Pharmaceuticals has been assigned the role to consider the foreign investment proposals under the Government approval route.

Pros and strengths

Asset-light business model and competitive products: The business model focuses on sourcing products of required quality through a manufacturer based on relationships with manufacturing partners. This allows for scaling operations without incurring capital expenditure on manufacturing facilities. The company operates on an asset-light business model, avoiding heavy investment in physical assets such as plants and machinery. This model supports capital efficiency, allows for expansion into new markets and distribution channels, and facilitates better cash flow management and lower risk.

Scalable business model: The business model is customer-centric and order-driven, requiring optimal utilization of resources, ensuring quality supply, and achieving economies of scale. Growth is supported by relationships with pharma manufacturers and the development of new markets and products by understanding customer needs and expanding the distribution network. The business model allows for scalability.

Wide and diverse range of product offerings: The company offers a range of products across Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, Goldline Wellness. Products are manufactured through contract manufacturing based on demand estimation and client requirements. The Company has the resources, experience, and network to introduce additional products.

Risks and concerns

Dependence on Goldline Pharma and Goldline Cardinal segments: The Company significantly depends on the Goldline Pharma and Goldline Cardinal segments for its revenue generation. The Goldline Pharma segment contributed 46.63%, 48.18%, 43.56%, and 51.53% to the Company’s revenue from operations during the nine months ended December 31, 2025, Fiscal 2025, Fiscal 2024, and Fiscal 2023, respectively, while the Goldline Cardinal segment contributed 26.46%, 24.64%, 28.36%, and 29.15%, respectively. Any reduction in demand for Goldline Pharma and Goldline Cardinal products could materially and adversely affect the company’s business, results of operations, and financial condition.

Dependence on limited geographies for revenue: It operates in limited geographies for a significant portion of its revenue. Its operations are based out of limited region like Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, Bihar, Chhattisgarh, Uttar Pradesh and Goa. The company derives a significant portion of its revenue from Maharashtra and Madhya Pradesh. Maharashtra contributed 44.36%, 47.54%, 50.50%, and 50.82% to the company’s total revenue as of December 31, 2025, March 31, 2025, March 31, 2024, and March 31, 2023, respectively, while Madhya Pradesh contributed 26.51%, 28.75%, 26.08%, and 22.02%, respectively. Its geographic concentration may have a have a material adverse effect on its business, results of operations and financial condition.

High working capital requirements: Its business requires significant amount of working capital and major portion of its working capital is utilized towards inventories and trade receivables. Its growing scale and expansion, if any, may result in increase in the quantum of current assets. Its inability to maintain sufficient cash flow, credit facility and other sources of funding, in a timely manner, or at all, to meet the requirement of working capital or pay out debts, could adversely affect its financial condition and result of its operations. Further, it has high outstanding amount due from its debtors which may result in a high risk in case of non-payment by these debtors. In case of any such defaults from its debtors, may affect its business operations and financials.

Outlook

Goldline Pharmaceutical is engaged in the business of marketing pharmaceutical products under the Goldline brand. Its products are divided into five categories: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Valiente. Its primary customers are distributors, who are further categorized as retailers and wholesalers. These distributors serve as the key channel through which its products reach the end-users. On the concern side, it relies entirely on third-party contract manufacturers for the manufacturing of its pharmaceutical products, and any failure or inability of such manufacturers to meet quality, regulatory, delivery or capacity requirements could adversely affect its business, results of operations and financial condition. Further, its business largely depends on the performance of its marketing team. 

The company is coming out with a maiden IPO of 27,00,000 equity shares of face value of Rs 10 each. The issue has been offered in a price band of Rs 41-43 per equity share. The aggregate size of the offer is around Rs 11.07 crore to Rs 11.61 crore based on lower and upper price band respectively. On performance front, during Fiscal 2025, revenue from operations stood at Rs 2,805.57 lakh, compared to Rs 2,356.60 lakh in Fiscal 2024, representing a 19.05% jump. The Profit After Tax (PAT) for Fiscal 2025 reached Rs 283.22 lakh, marking an increase from Rs 180.40 lakh in Fiscal 2024, up by 57%.

Meanwhile, it considers efficient inventory management as key to the part of its business. Its inventory management processes include product allocation and store planning based on an assessment of sales potential and requirements. It has strict inventory management and monitoring systems, in order to manage an appropriate level of inventory for each of its products, to ensure sufficient supply. It plans its inventory procurement by forecasting demand for QoQ based on its targeted sales and inventory turnover and also based on its previous quarter’s demand analysis. It generally endeavors to maintain inventory levels in line with customer demand. It continuously looks for opportunities to optimize its supply chain network as well as warehouse processes to optimize its efficiency and productivity. It relies on third party agencies logistics vehicles to transport the products. Additionally, it has contracts with third-party agencies specializing in logistics and courier services, including to ensure smooth and timely transportation of its products.

Pursuant to Regulation 30 read with Schedule III Part A Para A and Regulation 47 of SEBI Listing Regulations, Premier Polyfilm has informed that it enclosed the copies of Newspaper publication published in Financial Express, all editions and Jansatta, Delhi edition dated 10-05-2026 wherein extract of Audited Financial Results of the company for the quarter and year ended on 31st March,2026 were published.

The above information is a part of company’s filings submitted to BSE.

Msafe Equipments has informed that, the Company will host the Earnings Call with investors/analysts on Thursday, May 14, 2026 at 11:00 am (IST) to discuss the financial performance of the Company for the Half year and year ended March 31, 2026.